Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

midwives

- PMLiVE

Decision to withdraw Jevtana in England ‘flawed’

Urologists and oncologists attack NHS England’s de-listing of Sanofi’s drug

Sanofi reception

Generic competition for Sanofi’s Renvela hits UK market

Teva and others launch cheaper versions of the chronic kidney disease drug

Sanofi reception

Generic competition for Sanofi’s Renvela hits UK market

Teva and others launch cheaper versions of the chronic kidney disease drug

- PMLiVE

Genzyme cuts staff and signs $845m gene therapy pact

Alliance with Voyager Therapeutics revealed on the same day as job losses

Sanofi reception

Leaderless Sanofi sees strong growth

French firm confirms it will seek a new CEO this quarter

- PMLiVE

Sanofi launches inhaled insulin in US

Partners with MannKind on only diabetes treatment of its kind

Sanofi reception

Monthly dosing effective for Sanofi’s alirocumab

New data puts pressure on Amgen's evolocumab

- PMLiVE

Mind names YouTube star as first digital ambassador

Zoella launches #DontPanicButton campaign to raise awareness of anxiety

- PMLiVE

France’s taxes make CEO search harder, says Sanofi chairman

Weinberg tells former minister Arnaud Montebourgthat that tax burden is a turn-off for senior executives

Sanofi reception

Sanofi and Evotec discuss high-level outsourcing alliance

Partnership to focus on cancer drug discovery

Sanofi reception

Sanofi’s Priftin cleared for latent tuberculosis in the US

FDA approves Priftin with isoniazid for patients aged two years and older

- PMLiVE

The biosimilars are coming

Lilly on navigating the regulatory pathway for its insulin glargine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links